Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
暂无分享,去创建一个
M. Nussenzweig | P. Bieniasz | M. Jankovic | A. Gazumyan | T. Hatziioannou | C. Gaebler | F. Muecksch | Shlomo Finkin | F. Schmidt | M. Caskey | I. Shimeliovich | Victor Ramos | Zijun Wang | Juan P Dizon | Pilar Mendoza | A. Cho | M. Agudelo | M. Cipolla | Fengwen Zhang | Katrina G Millard | Eva Bednarski | Dennis J Schaefer-Babajew | Tarek Ben Tanfous | J. DaSilva | Martina Turroja | Mridushi Daga | Thiago Y Oliveria | M. Daga | Justin DaSilva | Katrina G. Millard | Dennis J. Schaefer-Babajew | Marianna Agudelo
[1] D. Cohen,et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections , 2021, medRxiv.
[2] M. Nussenzweig,et al. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York , 2021, Nature Communications.
[3] C. Schiffer,et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations , 2021, Immunity.
[4] R. Myers,et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.
[5] F. Rey,et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.
[6] Thomas P. Fabrizio,et al. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants , 2021, The New England journal of medicine.
[7] E. Wherry,et al. Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. , 2021, medRxiv.
[8] M. Diamond,et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses , 2021, Nature.
[9] C. Woods,et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies , 2021, Cell.
[10] A. Meola,et al. Memory B cells control SARS-CoV-2 variants upon mRNA vaccination of naive and COVID-19 recovered individuals , 2021, bioRxiv.
[11] C. Rice,et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection , 2021, Nature.
[12] J. Bloom,et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection , 2021, Science Translational Medicine.
[13] H. van Bakel,et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 , 2021, Cell.
[14] James C. Crosby,et al. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[15] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[16] J. Mascola,et al. Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants , 2021, bioRxiv.
[17] L. Ma,et al. Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine Booster , 2021, medRxiv.
[18] L. Abu-Raddad,et al. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.
[19] B. Chain,et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose , 2021, Science.
[20] Henry A. Utset,et al. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets , 2021, Immunity.
[21] R. Darnell,et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants , 2021, The New England journal of medicine.
[22] Aaron M. Rosenfeld,et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination , 2021, Science Immunology.
[23] L. Stamatatos,et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection , 2021, Science.
[24] D. Fremont,et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies , 2021, Nature Medicine.
[25] L. Walker,et al. Prolonged evolution of the human B cell response to SARS-CoV-2 infection , 2021, Science Immunology.
[26] M. Nussenzweig,et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants , 2021, Nature.
[27] Bjoern Peters,et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.
[28] D. Stuart,et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.
[29] C. Rice,et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA , 2020, Science Translational Medicine.
[30] J. Mascola,et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination , 2020, The New England journal of medicine.
[31] A. Meola,et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response , 2020, Cell.
[32] M. Nussenzweig,et al. Evolution of Antibody Immunity to SARS-CoV-2 , 2020, bioRxiv.
[33] C. Cordon-Cardo,et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.
[34] M. Nussenzweig,et al. Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates , 2020, Cell.
[35] Xinwen Chen,et al. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques , 2020, Nature Communications.
[36] Lisa E. Gralinski,et al. A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2 , 2020, Cell.
[37] A. Mehta,et al. Influenza vaccine–induced human bone marrow plasma cells decline within a year after vaccination , 2020, Science.
[38] C. Rice,et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.
[39] C. Rice,et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals , 2020, Nature.
[40] C. Rice,et al. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.
[41] L. Gieselmann,et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients , 2020, Cell.
[42] C. Rice,et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses , 2020, bioRxiv.
[43] L. Stamatatos,et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation , 2020, Immunity.
[44] M. Nussenzweig,et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies , 2020, bioRxiv.
[45] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[46] C. Cunningham-Rundles,et al. A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.
[47] M. V. van Breemen,et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.
[48] E. Holmes,et al. A new coronavirus associated with human respiratory disease in China , 2020, Nature.
[49] T. Kurosaki,et al. Restricted Clonality and Limited Germinal Center Reentry Characterize Memory B Cell Reactivation by Boosting , 2019, Cell.
[50] Peter D. Kwong,et al. cAb-Rep: A Database of Curated Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody Prevalence , 2019, bioRxiv.
[51] James E. Crowe,et al. High frequency of shared clonotypes in human B cell receptor repertoires , 2019, Nature.
[52] D. Weissman,et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[53] Steven H. Kleinstein,et al. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data , 2015, Bioinform..
[54] Hao Wu,et al. Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow. , 2015, Immunity.
[55] M. Jenkins,et al. Apoptosis and antigen affinity limit effector cell differentiation of a single naïve B cell , 2015, Science.
[56] Mark Mulligan,et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells , 2012, Proceedings of the National Academy of Sciences.
[57] B. Pulendran,et al. Rapid and Massive Virus-Specific Plasmablast Responses during Acute Dengue Virus Infection in Humans , 2012, Journal of Virology.
[58] R. Maul,et al. Different B Cell Populations Mediate Early and Late Memory During an Endogenous Immune Response , 2011, Science.
[59] Patrick C. Wilson,et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus , 2008, Nature.
[60] Nichole E Carlson,et al. Duration of humoral immunity to common viral and vaccine antigens. , 2007, The New England journal of medicine.
[61] R. Ahmed,et al. Humoral immunity due to long-lived plasma cells. , 1998, Immunity.
[62] D. Calado,et al. Germinal Centers , 2017, Methods in Molecular Biology.
[63] Michael T. Rosenstein,et al. Corresponding Author’s , 1993 .